The charts on this page feature a breakdown of the total annual pay for the top executives at ELI LILLY & Co as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ELI LILLY & Co income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ELI LILLY & Co annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Enrique A. Conterno
Senior Vice President and President, Lilly Diabetes and President, Lilly USA
Total Cash $1,933,750 Equity $3,026,400 Other $50,000 Total Compensation $5,010,150
Michael J. Harrington
Senior Vice President and General Counsel
Total Cash $1,886,825 Equity $2,968,200 Other $53,603 Total Compensation $4,908,628
David A. Ricks
Chairman, President, and Chief Executive Officer
Total Cash $4,319,000 Equity $12,222,000 Other $84,000 Total Compensation $16,625,000
Daniel M. Skovronsky M.D., Ph.D.
Senior Vice President, Chief Scientific Officer, and President, Lilly Research Laboratories
Total Cash $2,088,450 Equity $4,074,000 Other $54,000 Total Compensation $6,216,450
Joshua L. Smiley
Senior Vice President and Chief Financial Officer
Total Cash $2,078,781 Equity $3,142,800 Other $53,750 Total Compensation $5,275,331
For its 2019 fiscal year, ELI LILLY & Co, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
David A. Ricks CEO Pay $21,283,242 Median Employee Pay $96,290 CEO Pay Ratio 221:1
For its 2018 fiscal year, ELI LILLY & Co, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Carolyn R. Bertozzi Total Cash $294,000
Ellen R. Marram Total Cash $368,000
J. Erik Fyrwald Total Cash $299,205
Jackson P. Tai Total Cash $326,000
Jamere Jackson Total Cash $294,000
Juan R. Luciano Total Cash $299,000
Karen Walker Total Cash $24,500
Katherine Baicker, Ph.D. Total Cash $302,000
Kathi P. Seifert Total Cash $310,841
Marschall S. Runge, M.D., Ph.D Total Cash $295,000
Michael L. Eskew Total Cash $315,000
R. David Hoover Total Cash $156,250
Ralph Alvarez Total Cash $306,000
William G. Kaelin, Jr., Dr. Total Cash $309,000

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.